Posted by Albert Gersh - June 19, 2015
Iran’s full disclosure of its atomic weapons research is necessary for verification purposes and it is not possible for the United States to possess “absolute knowledge” on this matter, according to experts and lawmakers quoted by Eli Lake and Josh Rogin in a Friday piece in Bloomberg View.
On Tuesday, Secretary of State John Kerry told reporters
, “We have absolute knowledge with respect to the certain military activities they were engaged in.” Senator Chris Coons (D-Del.) told Lake and Rogin that “he and other senators would judge the quality of a final Iran deal in part on how the deal compels Iran to fess up about its past weapons work.” Kerry’s statements are undercut by the Director General of the International Atomic Energy Agency, Yukiya Amano, who said
in March, “We don’t know what they did in the past… And that is why we cannot say that all the activities in Iran is [sic] in peaceful purposes.” Kerry also said that the administration is not “fixated” on Iran’s past and is focusing on the future. These statements came on the heels of an Associated Press repor
t last week that the administration is willing to sign a final agreement omitting an Iranian disclosure of their past nuclear research.
The Obama administration has repeatedly asserted that such disclosure is absolutely necessary for a deal. In April, Kerry said about this matter, “They have to do it. It will be done. If there’s going to be a deal, it will be done…It will be part of a final agreement. It has to be.”
Senator Bob Menendez (D-NJ) called Kerry’s suggestion that Iranian disclosure was unnecessary “unacceptable”: “It has been a fundamental question to which we need – not just want – a full and verifiable answer…and that has been the case as long as I’ve been working to prevent Iran from becoming a nuclear-weapons state.” William Tobey of Harvard University’s Belfer Center for Science and International Affairs, wrote in Foreign Policy Friday, “A complete and correct understanding of all of Iran’s military nuclear activities is imperative for effective verification…Iran’s unwillingness to resolve the ‘possible military dimensions’ issue is direct evidence regarding its willingness to comply with a future nuclear deal.”
A 25-year-old man was killed and a second man wounded in a terror attack near Dolev, northwest of Jerusalem in the West Bank, The Times of Israel reported today.
The 25-year-old was shot in the upper body near the settlement of Dolev, northwest of Jerusalem. He was found unconscious and transferred to Tel Hashomer Hospital by IDF helicopter where he died over an hour after the attack.
A second man was moderately hurt in the attack and was also being treated at Tel Hashomer.
A large deployment of soldiers aided by Israel Police were currently searching for at least one shooter.
According to Ynet, the men had been flagged down by a pedestrian.
Two 25-year-old Israelis were traveling in the area inside a vehicle when a Palestinian signaled for them to stop as if to ask for help before firing on them from point-blank range. Magen David Adom and a large number of IDF troops were rushed to the area which was cordoned off as searches began for a suspect.
While several other Israeli companies are pioneering treatment options for attention-deficit/hyperactivity disorder (ADHD), Nes Ziona-based NeuroTechnology Solutions has put its development efforts into Internet-based software technologies that help clinicians better diagnose and monitor attention problems.
The system, Moxo Analytics ,
has different versions for children and adults, and delivers scores on a range of developmental, cognitive and behavioral components of ADHD making it easier to decide how to help the person suffering from the disorder. Moxo already has the European Union’s CE mark and was introduced in Israel nearly four years ago and now claims 40 percent of the market. Clinicians in Canada, Turkey, Poland, South Africa, Mexico and Spain are using it too, and other markets are on the horizon. According to the ADHD Institute, the worldwide prevalence of ADHD is between 5.29 and 7.1 percent in people under 18 years old. It affects up to one in 20 American children, more often boys than girls, and often continues into adulthood. “Our company was established seven years ago by three entrepreneurs with a personal interest in ADHD and a creative approach that drew its innovation from the gaming industry. With that in mind, they developed the Moxo test – a next-generation online tool to enhance the clinician’s assessment and treatment process,” says NeuroTechnologies business development manager Karina Rubinstein. With input from a well-known Israeli pediatric neurologist specializing in ADHD, Moxo was designed to simulate today’s information-filled computer, tablet and smartphone environments. Unlike earlier diagnostic tests still widely used across the world, Moxo presents the person being tested with a set of auditory and visual “distractors.” (via Israel21c